Amanita phalloides species mushrooms containing
alpha-amanitin (α-AMA) are responsible for the majority of fatal mushroom intoxications and can lead to severe
poisonings resulting in hepatotoxicity and
acute hepatic failure. Existing antidotes, such as
silibinin, are not sufficiently effective in the prevention and/or resolution of α-AMA-induced hepatotoxicity. We investigated the effects of
resveratrol on α-AMA-induced hepatotoxicity and compared with
silibinin, a known
antidote using in vivo and in vitro toxicity models. In the in vivo protocol,
resveratrol (30 mg/kg) was given simultaneously with α-AMA (α-AMA + SR) or 12 (α-AMA + 12R) or 24 (α-AMA + 24R) hr after α-AMA administration.
Silibinin (5 mg/kg) (α-AMA + Sil) and
normal saline (α-AMA + NS) were given simultaneously with α-AMA. We found that liver
transaminase levels in α-AMA + SR and α-AMA + 12R groups and histomorphologic injury score in the α-AMA + SR, α-AMA + 12R, α-AMA + 24R and α-AMA + Sil groups were significantly lower than that of the α-AMA + NS group.
Resveratrol decreased mononuclear cell infiltration,
necrosis and active
caspase-3 immunopositivity in the liver. In the in vitro protocol, the effects of
resveratrol and
silibinin were evaluated in a reduction in cell viability induced by α-AMA in THLE-2 and THLE-3 hepatocytes. Neither
resveratrol nor
silibinin was found to be effective in increasing cell viability decreased by α-AMA + NS. As a conclusion,
resveratrol was found to be effective in α-AMA-induced hepatotoxicity with its anti-inflammatory properties in in vivo conditions. It is a promising compound with the potential for use in the treatment of hepatotoxicity associated with Amanita phalloides type
mushroom poisonings.